1Department of Anesthesiology and Intensive Care Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan. 2Department of Ultrastructural Research, Institute for Frontier Medical Sciences, Kyoto University, Japan*Corresponding author
Accepted for publication: March 2, 2001
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Br J Anaesth 2001; 87: 26671
Keywords: complications, acute respiratory distress syndrome; aerosols; equipment, nebulizers; anaesthetic techniques, inhalation; lung, surfactant; rat
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Main procedure
With the approval of the Animal Care Committee of the Kanazawa University School of Medicine, 36 male Wistar rats weighing between 320 and 440 g were anaesthetized with an i.p. injection of pentobarbital sodium (30 mg kg1), and the lungs intubated through a tracheotomy. One femoral artery was cannulated to allow monitoring of arterial pressure and removal of blood samples. Lactated Ringers solution containing a neuromuscular blocking agent (0.02 mg ml1 pancuronium bromide) was continuously infused at a rate of 10 ml kg1 h1 through one femoral vein. Pentobarbital sodium (a single dose of 15 mg kg1) was injected into the peritoneal cavity when additional anaesthesia was necessary.
The experiment was always performed concurrently on three rats, which made up one set, each rat being connected in parallel to a pressure-controlled ventilator (Servo 900B, Siemens-Elema, Solna, Sweden) delivering 100% oxygen at a frequency of 40 breaths min1 with an inspiration time of 50%, and a fixed peak inspiratory pressure of 25 cm H2O. At the beginning of the experiment, the positive end-expiratory pressure (PEEP) was set at 7.5 cm H2O with the aid of a variable resistor (E037E, Siemens-Elema). After registration of the baseline value for arterial blood gases, PEEP was reduced to 0 cm H2O, and 40 mg kg1 of endotoxin (E. coli O111:B4, Difco Laboratories, Detroit, MI, USA), suspended in normal saline (20 mg ml1), was injected into the lungs through the tracheal tube over 1 s. Arterial blood samples were analysed for PaO2 every 30 min. The same dose was re-administered to an individual rat whose PaO2 was higher than 53 kPa 30 min after the first injection.
All three rats in the set were ventilated with these ventilatory settings until PaO2 decreased to less than 27 kPa; this oxygen index value was chosen based on the criteria for ARDS patients.14 Then, the PEEP was increased in increments of 2.5 cm H2O. Sequences of increment in PEEP and ventilation were repeated until the PaO2 decreased to less than 27 kPa despite a PEEP of 7.5 cm H2O. Then, lung oedema fluid in the airway was removed by tracheal suction with a fine catheter. When the PaO2 values of all three rats in a set remained at less than 27 kPa 15 min after tracheal suctioning, experimental ARDS was considered to be fully developed. One rat in the set was randomly assigned to a control group and did not receive any aerosol into the airway. The other two rats were randomly assigned to two of three aerosolized surfactant groups as described below.
Rats in the AS-30, AS-60, and AS-120 groups underwent inhalation of aerosolized MNS for 30, 60, and 120 min, respectively. For this purpose, the rats were connected to an inhalation circuit constructed as a branch circuit, to which the ventilator delivered oxygen under the same conditions as for the main circuit.15 An ultrasonic nebulizer (NE-U06, Omron, Tokyo, Japan), with its blowing system shut off, was positioned 7 cm proximal to the tracheal tube. A 3-ml aliquot of the MNS suspension was placed in the reservoir of the nebulizer, which produced an aerosol (mean droplet diameter, 3.4 (SD 1.2) µm) by means of ultrasound (2.4 MHz, 30 W).15 The moment when the aerosol inhalation was initiated was termed the starting point. Another 3 ml of the fresh MNS suspension was added to the reservoir every 15 min. After completion of the inhalation, the rats were reconnected to the original ventilatory circuit. Arterial blood samples were then evaluated sequentially for PaO2, PaCO2 and base excess (BE) using a conventional analyser (ABL-520, Radiometer, Copenhagen, Denmark) until 180 min after the starting point. Tracheal suction was performed 5 min before each blood gas analysis. A fixed volume of 0.5 ml of sodium bicarbonate (1 Eq litre1) was administered for correction of metabolic acidosis after each blood gas analysis if BE was lower than 5 mEq litre1
At the end of the experiment (i.e. 180 min after the starting point), a sublethal dose of pentobarbital was administered, after which the tracheal tube was plugged to cause absorption atelectasis followed by death. Next, the thorax was opened and all rats were connected in parallel to an apparatus for static pressure-volume recordings of the lung.16 Airway pressure was raised in a stepwise manner from 0 to 30 cm H2O, and then lowered, also in a stepwise manner, to 0 cm H2O, with a 1-min period of stress relaxation at each 5-cm H2O level. These volume measurements were corrected for gas compression.
Additional procedure
To assess the distribution of aerosolized MNS in the lungs, an additional experiment was performed on three pairs of lung-lavaged rats.17 The rats were mechanically ventilated with a peak inspiratory pressure of 25 cm H2O and a PEEP of 7.5 cm H2O using pure oxygen, and underwent lung-lavage with normal saline (40 ml kg1, 37°C) six times. One rat of the pair was ventilated for 60 min without administration of any aerosolized MNS, while the other rat of the pair was subjected to inhalation of aerosolized MNS for 60 min in the same manner as described in the main procedure. Rats were then killed and their thorax opened. The lungs were expanded at an airway pressure of 10 cm H2O, and were fixed by immersion of the whole body in a formalin solution (10%) for 3 h. The lungs were then removed and further fixed in formalin for several weeks.
Lung sections were examined for localization of SP-B with the aid of monoclonal mouse anti-SP-B antibody (8B5E).18 This antibody binds with SP-B derived from both rat and pig so that both endogenous and exogenous surfactants could be detected. In brief, the lung sections were first counterstained with Meyers haematoxylin and intrinsic peroxidase activity was inhibited by means of 0.3% hydrogen peroxide in methanol for 30 min. Next, they were incubated with anti-SP-B antibody in phosphate-buffered saline (PBS) for 30 min after blocking non-specific binding sites with 5% bovine serum albumin in PBS. The sections were immersed in biotinylated anti-mouse IgG (H+L) (Vector Laboratories, Inc., Burlingame, CA, USA) and then in a solution of avidin-biotinylated horseradish peroxidase complex (VECTASTAIN ABC kit, Vector Laboratories). The final peroxidase reaction was performed with 0.05% diaminobenzidine-tetrahydrochloride and 0.01% hydrogen peroxide. The sections serving as controls were treated in the same manner but without primary antibody.
Statistical analysis
Data are presented as mean (SD). Differences in survival rates and the proportion of rats that needed second injections of endotoxin were assessed with Fishers exact test. Other numerical data were assessed by means of one- or two-way analysis of variance, modified for repeated measures, using the SuperANOVATM software applications (Abacus Concepts, Berkeley, CA, USA) for the MacintoshTM computer (Apple Computer, Cupertino, CA, USA). When inter- and/or intra-group differences occurred, they were further analysed with contrasts. P<0.05 was considered significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
Deflation limbs of the static pressure-volume recordings of the lung are shown in Fig. 2. Volumes of the AS-30 group did not differ significantly from those of the control group at any pressure. The volumes of the AS-60 group were significantly greater than those of the control group at airway pressures from 30 (maximal pressure) to 15 cm H2O, while significant differences between the AS-120 and the control groups were observed at airway pressures from 30 to 5 cm H2O.
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
It was reported that slow continuous instillation of surfactant into the airway did not change arterial pressure in lung-lavaged rabbits.9 However, arterial blood gases were not improved because of inhomogeneous distribution of surfactant in the lung. We have shown that inhalation of aerosolized MNS improves blood gas exchange and lung mechanics without changing arterial pressure in rats with experimental ARDS caused by endotoxin.10 A recent study using a model of isolated perfused rabbit lung19 demonstrated that aerosolized surfactant improved ventilation/perfusion mismatch caused by inhalation of a detergent, Tween 20, and that a slow instillation of surfactant did not. The inhalation method, therefore, is superior to slow instillation.
Oxygenation index (PaO2 FIO21) value for the criteria of ARDS is below 27 kPa and that of acute lung injury is below 40 kPa.14 In the present study, the oxygenation index of all the rats decreased to well below the criteria of ARDS (11.3 kPa) at the pre-starting point, as the result of the injection of the endotoxin. Inhalation of aerosolized MNS for 30 or 60 min initially restored gas exchange, but PaO2 deteriorated after termination of the inhalation. In contrast, inhalation for 120 min caused an increase in PaO2 to 46 kPa at the end of inhalation, and this increase continued after the end of the inhalation period. Inhalation for 120 min also improved PaCO2 and static lung volume more than that for 30 or 60 min.
It is remarkable that the final PaO2 value in AS-120 group was as high as the peak value for rats given 100 mg kg1 by instillation of MNS into the airway in our previous study.10 In that study, intact rats were subjected to inhalation of MNS mixed with 99mTcO4. Only 4.2% of the total radioactivity was deposited in the lung. Based on this deposition rate, it was estimated that less than 64 mg kg1 of MNS was deposited in the lungs of the AS-120 group rats as 600 mg was used for inhalation. Inhalation of aerosolized MNS was, therefore, more effective than bolus instillation in terms of the actual amount deposited.
In our additional procedure, deposition of the aerosolized MNS was assessed with the aid of anti-SP-B antibody. Location of aerosol deposition depends on the size of the aerosol.20 The diameter of the aerosolized MNS produced by our nebulizer (3.4 (1.2) µm) is close to the ideal size for alveolar deposition (23 µm).20 In the rats subjected to repeated lung-lavage without inhalation of aerosolized MNS, there was little staining along the airway or alveolar walls, indicating the effective removal of endogenous surfactant. In rats inhaling aerosolized MNS, the terminal airways and some alveolar walls were stained with peroxide, indicating the deposition of exogenous surfactant. A theoretical model for replacement therapy suggests that surfactant instilled into the airway moves to the alveoli when surface tension in the alveoli is elevated.21 We believe that aerosolized MNS deposited in both of the alveolar walls and the airways participated in reducing the alveolar surface tension in the main experiment.
In the present study, two of eight rats in the AS-120 group died because of hypotension, although PaO2 values were maintained higher than 27 kPa. There were no significant differences in mortality rates among the four groups. Endotoxin causes hypotension and massive accumulation of ascites in rats, even when injected through the trachea.11 Treatment of hypotension may be important to assess the effects on mortality rate. It was reported that a modified bovine surfactant inhibited production of superoxide by neutrophils obtained from hamster with neutrophil alveolitis and promoted apoptosis of neutrophils in vitro.22 The effect of surfactant on neutrophils also needs further investigation.
We conclude that inhalation of aerosolized MNS can improve gas exchange and lung mechanics depending on duration of administration in the experimental setting used for this study. Inhalation for 2 h improved gas exchange to the same extent as was attained with bolus instillation. Prolonged inhalation of aerosolized surfactant, therefore, appears to be suitable for ARDS patients especially with circulatory instability.
![]() |
Acknowledgements |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J 1994; 7: 37291
3 Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 147: 21833[ISI][Medline]
4 Kobayashi T, Nitta K, Ganzuka M, et al. Inactivation of exogenous surfactant by pulmonary edema fluid. Pediatr Res 1991; 29: 3536[Abstract]
5 Nitta K, Kobayashi T. Impairment of surfactant activity and ventilation by proteins in lung edema fluid. Respir Physiol 1994; 95: 4351[ISI][Medline]
6 Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334: 141721
7 Walmrath D, Gunther A, Ghofrani HA, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996; 154: 5762[Abstract]
8 Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155: 130915[Abstract]
9 Segerer H, van Gelder W, Angenent FWM, et al. Pulmonary distribution and efficacy of exogenous surfactant in lung-lavaged rabbits are influenced by the instillation technique. Pediatr Res 1993; 34: 4904[Abstract]
10 Tashiro K, Yamada K, Li WZ, Matsumoto Y, Kobayashi T. Aerosolized and instilled surfactant therapies for acute lung injury caused by intratracheal endotoxin in rats. Crit Care Med 1996; 24: 48894[ISI][Medline]
11 Tashiro K, Li WZ, Yamada K, Matsumoto Y, Kobayashi T. Surfactant replacement reverses respiratory failure induced by intratracheal endotoxin in rats. Crit Care Med 1995; 23: 14956[ISI][Medline]
12 Kobayashi T, Kataoka H, Murakami S, and Haruki S. A case of idiopathic respiratory distress syndrome treated by newly developed surfactant (Surfactant CK). J Jap Med Soc Biol Interface 1981; 12: 16.
13 Robertson B, Curstedt T, Grossmann G, et al. Prolonged ventilation of the premature newborn rabbit after treatment with natural or apoprotein-based artificial surfactant. Eur J Pediatr 1988; 147: 16873[ISI][Medline]
14 Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. Intensive Care Med 1994; 20: 22532[ISI][Medline]
15 Li WZ, Chen WM, Kobayashi T. Aerosolized surfactant reverses respiratory failure in lung-lavaged rats. Acta Anaesthesiol Scand 1994; 38: 828[ISI][Medline]
16 Enhörning G, Robertson B. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 1972; 50: 5866[Abstract]
17 Lachmann B, Robertson B, Vogel J. In vivo lung lavage as an experimental model of the respiratory distress syndrome. Acta Anaesthesiol Scand 1980; 24: 2316[ISI][Medline]
18 Suzuki Y, Kogishi K, Fujita Y, Kina T, Nishikawa S. A monoclonal antibody to the 15,000 dalton protein associated with porcine pulmonary surfactant. Exp Lung Res 1986; 11: 6173[ISI][Medline]
19 Schermuly R, Schmehl T, Günther A, et al. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. Impact on gas exchange. Am J Respir Crit Care Med 1997; 156: 44553
20 Cushing IE, Miller WF. Nebulization therapy. In: Safer P. ed. Respiratory Therapy. Philadelphia: F A Davis, 1965; 169218
21 Espinosa FF, Kamm RD. Bolus dispersal through the lungs in surfactant replacement therapy. J Appl Physiol 1999; 86: 391410
22 Suwabe A, Otake K, Yakuwa N, et al. Artificial surfactant (Surfactant TA) modulates adherence and superoxide production of neutrophils. Am J Respir Crit Care Med 1998; 158: 18909